Costs Associated With Intravenous Darbepoetin Versus Epoetin Therapy in Hemodialysis Patients: A Randomized Controlled Trial

BACKGROUND: Anemia of chronic kidney disease is associated with adverse outcomes and a reduced quality of life. Erythropoiesis-stimulating agents (ESAs) have improved anemia management, and 2 agents are available in Canada, epoetin alfa (EPO) and darbepoetin alfa (DA). EPO and DA are considered equa...

Descripción completa

Detalles Bibliográficos
Autores principales: Woodland, Andrea L., Murphy, Sean W., Curtis, Bryan M., Barrett, Brendan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502937/
https://www.ncbi.nlm.nih.gov/pubmed/28717516
http://dx.doi.org/10.1177/2054358117716461

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502937/
https://www.ncbi.nlm.nih.gov/pubmed/28717516
http://dx.doi.org/10.1177/2054358117716461

Ejemplares similares